Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [18F]flortaucipir study

被引:6
作者
O'Connor, Antoinette [1 ,2 ]
Cash, David M. [1 ]
Poole, Teresa [1 ,3 ]
Markiewicz, Pawel J. [4 ]
Fraser, Maggie R. [1 ]
Malone, Ian B. [1 ]
Jiao, Jieqing [4 ]
Weston, Philip S. J. [1 ]
Flores, Shaney [5 ]
Hornbeck, Russ [5 ]
McDade, Eric [6 ]
Schoell, Michael [1 ,7 ]
Gordon, Brian A. [5 ]
Bateman, Randall J. [6 ]
Benzinger, Tammie L. S. [5 ]
Fox, Nick C. [1 ,2 ]
机构
[1] UCL Queen Sq Inst Neurol, Dementia Res Ctr, London, England
[2] UK Dementia Res Inst UCL, London, England
[3] London Sch Hyg & Trop Med, Dept Med Stat, London, England
[4] UCL, Ctr Med Image Comp Med Phys & Biomed Engn, London, England
[5] Washington Univ St Louis, Dept Radiol, St Louis, MO USA
[6] Washington Univ St Louis, Dept Neurol, St Louis, MO USA
[7] Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden
基金
美国国家卫生研究院; 加拿大健康研究院; 英国医学研究理事会;
关键词
POSITRON-EMISSION-TOMOGRAPHY; PET PATTERNS; F-18-AV-1451; DEPOSITION; PHENOTYPE; TAUOPATHY; TRACER; BRAIN; ONSET;
D O I
10.1186/s13195-023-01234-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cortical tau accumulation is a key pathological event that partly defines Alzheimer's disease (AD) onset and is associated with cognitive decline and future disease progression. However, an improved understanding of the timing and pattern of early tau deposition in AD and how this may be tracked in vivo is needed. Data from 59 participants involved in two longitudinal cohort studies of autosomal dominant AD (ADAD) were used to investigate whether tau PET can detect and track presymptomatic change; seven participants were symptomatic, and 52 were asymptomatic but at a 50% risk of carrying a pathogenic mutation. All had baseline flortaucipir (FTP) PET, MRI and clinical assessments; 26 individuals had more than one FTP PET scan. Standardised uptake value ratios (SUVRs) in prespecified regions of interest (ROIs) were obtained using inferior cerebellar grey matter as the reference region. We compared the changes in FTP SUVRs between presymptomatic carriers, symptomatic carriers and non-carriers, adjusting for age, sex and study site. We also investigated the relationship between regional FTP SUVRs and estimated years to/from symptom onset (EYO). Compared to both non-carriers and presymptomatic carriers, FTP SUVRs were significantly higher in symptomatic carriers in all ROIs tested (p < 0.001). There were no significant regional differences between presymptomatic carriers and non-carriers in FTP SUVRs, or their rates of change (p > 0.05), although increased FTP signal uptake was seen posteriorly in some individuals around the time of expected symptom onset. When we examined the relationship of FTP SUVR with respect to EYO, the earliest significant regional difference between mutation carriers and non-carriers was detected within the precuneus prior to estimated symptom onset in some cases. This study supports preliminary studies suggesting that presymptomatic tau tracer uptake is rare in ADAD. In cases where early uptake was seen, there was often a predilection for posterior regions (the precuneus and post-cingulate) as opposed to the medial temporal lobe, highlighting the importance of examining in vivo tau uptake beyond the confines of traditional Braak staging.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology
    Smith, Ruben
    Wibom, Moa
    Pawlik, Daria
    Englund, Elisabet
    Hansson, Oskar
    JAMA NEUROLOGY, 2019, 76 (03) : 310 - 317
  • [2] Imaging Aβ and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451
    Firouzian, Azadeh
    Whittington, Alex
    Searle, Graham E.
    Koychev, Ivan
    Zamboni, Giovanna
    Lovestone, Simon
    Gunn, Roger N.
    EJNMMI RESEARCH, 2018, 8
  • [3] Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers
    Gordon, Brian A.
    Blazey, Tyler M.
    Christensen, Jon
    Dincer, Aylin
    Flores, Shaney
    Keefe, Sarah
    Chen, Charles
    Su, Yi
    McDade, Eric M.
    Wang, Guoqiao
    Li, Yan
    Hassenstab, Jason
    Aschenbrenner, Andrew
    Hornbeck, Russ
    Jack, Clifford R., Jr.
    Ances, Beau M.
    Berman, Sarah B.
    Brosch, Jared R.
    Galasko, Douglas
    Gauthier, Serge
    Lah, James J.
    Masellis, Mario
    van Dyck, Christopher H.
    Mintun, Mark A.
    Klein, Gregory
    Ristic, Smiljana
    Cairns, Nigel J.
    Marcus, Daniel S.
    Xiong, Chengjie
    Holtzman, David. M.
    Raichle, Marcus E.
    Morris, John C.
    Bateman, Randall J.
    Benzinger, Tammie L. S.
    BRAIN, 2019, 142 : 1063 - 1076
  • [4] Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease
    Quiroz, Yakeel T.
    Sperling, Reisa A.
    Norton, Daniel J.
    Baena, Ana
    Arboleda-Velasquez, Joseph F.
    Cosio, Danielle
    Schultz, Aaron
    Lapoint, Molly
    Guzman-Velez, Edmarie
    Miller, John B.
    Kim, Leo A.
    Chen, Kewei
    Tariot, Pierre N.
    Lopera, Francisco
    Reiman, Eric M.
    Johnson, Keith A.
    JAMA NEUROLOGY, 2018, 75 (05) : 548 - 556
  • [5] Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease
    Kang, Jae Myeong
    Lee, Sang-Yoon
    Seo, Seongho
    Jeong, Hye Jin
    Woo, Sung-Ho
    Lee, Hyon
    Lee, Yeong-Bae
    Yeon, Byeong Kil
    Shin, Dong Hoon
    Park, Kee Hyung
    Kang, Hyejin
    Okamura, Nobuyuki
    Furumoto, Shozo
    Yanai, Kazuhiko
    Villemagne, Victor L.
    Seong, Joon-Kyung
    Na, Duk L.
    Ido, Tatsuo
    Cho, Jaelim
    Lee, Kyoung-Min
    Noh, Young
    NEUROBIOLOGY OF AGING, 2017, 59 : 210 - 219
  • [6] Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer's disease
    Cho, Hanna
    Baek, Min Seok
    Lee, Hye Sun
    Lee, Jae Hoon
    Ryu, Young Hoon
    Lyoo, Chul Hyoung
    ALZHEIMERS RESEARCH & THERAPY, 2020, 12 (01)
  • [7] Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer's Disease
    Wang, Ying
    Cai, Li
    Zhou, Kaixiang
    Cui, Mengchao
    Yao, Shaobo
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, 9
  • [8] In vivo imaging of tau deposition in Alzheimer's disease using both [18F]-THK5317 and [18F]-S16: A pilot human study
    Fu, Liping
    Zhang, Jinming
    Zhou, Kaixiang
    Zhang, Xiaojun
    Xie, Hengge
    Zhu, Mingwei
    Cui, Mengchao
    Wang, Ruimin
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [9] Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease
    Rodriguez-Vieitez, Elena
    Saint-Aubert, Laure
    Carter, Stephen F.
    Almkvist, Ove
    Farid, Karim
    Scholl, Michael
    Chiotis, Konstantinos
    Thordardottir, Steinunn
    Graff, Caroline
    Wall, Anders
    Langstrom, Bengt
    Nordberg, Agneta
    BRAIN, 2016, 139 : 922 - 936
  • [10] Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study
    Chen, Shi-Dong
    Lu, Jia-Ying
    Li, Hong-Qi
    Yang, Yu-Xiang
    Jiang, Jie-Hui
    Cui, Mei
    Zuo, Chuan-Tao
    Tan, Lan
    Dong, Qiang
    Yu, Jin-Tai
    TRANSLATIONAL PSYCHIATRY, 2021, 11 (01)